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ABSTRACT 
 Organ transplantation  has been the standard of care for end-stage organ failure.  
While one-year renal allograft survival has increased to over 90% in the past couple of 
decades with the use of new immunosuppressants, the long term survival of kidney 
allografts have remained the same due to unchanged rate of chronic rejection.  Even with 
acceptance of renal allografts, patients require lifelong use of immunosuppressants.  The 
induction of transplantation tolerance may allow for patients to receive transplants 
without having to deal with the side effects of immunosuppression.  Using a unique 
miniature swine model, we have demonstrated uniform induction of tolerance in 
recipients of MHC class-I mismatched renal allografts with 12 days of high Cyclosporine 
A.  Transplantation tolerance in this model is induced and maintained by regulatory T 
cells.  In our study, we used this model to attempt to induce tolerance in naïve recipients 
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through adoptive transfer of donor primed or unprimed peripheral regulatory cells and/or 
kidneys from long-term tolerant donor-matched swine.  SLA
dd 
miniature swine received 
150 rads of whole body irradiation and class I-mismatched SLA
gg 
kidneys from naïve 
pigs with or without co-transplanted kidneys and/or cells from long-term tolerant SLA
dd 
recipients of SLA
gg 
kidneys.  Naïve kidneys transplanted without a long-term tolerant 
kidney were acutely rejected.  Recipients of naïve kidneys co-transplanted with donor 
primed cells and kidney grafts from long-term tolerant animals had extended survival 
times for the naïve renal grafts:  2 out of 3 animals in this group became long-term 
tolerant and the remaining had an extended graft survival (28 days).  
These studies demonstrate the first successful adoptive transfer of tolerance in 
large animals.  The data suggest that the tolerated kidneys and cells have regulatory 
effects, likely due to regulatory T cells that can induce and maintain tolerance.  The 
potency and efficacy of regulatory T cells has been shown in our study and could 
potentially be exploited to provide for therapies to induce and maintain tolerance. 
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INTRODUCTION 
“Organ transplantation is the standard of care for end-stage kidney 
failure, in terms of survival, quality of life and cost effectiveness 
compared with other replacement therapies and remains the only 
available treatment for persons with end stage failure of other solid 
organs” ("Pages-Facts," 2013).   
 
Patients throughout the world have lifesaving transplants and patients with kidney failure 
have a better life expectancy and quality of life compared with dialysis (Bishop et al., 
2011).  In 2010 alone, there were 106,900 solid organs transplanted worldwide and 
73,180 of the transplants were kidney transplants.  Those 2010 data are based on the 
Global Observatory on Donation and Transplantation Data (GODT) data, produced by 
the WHO-ONT collaboration.  While most solid organs are procured from the deceased, 
kidney transplants can come from appropriately matched living donors with minor risks 
("Pages-Facts," 2013). 
Since 1954 when Murray et al. completed the first successful kidney transplant 
between identical twins, there has been considerable advancement in the science behind 
kidney transplantation (Murray & Holden, 1954).  Although transplantation biology was 
in its primitive state, it was known from animal models that transplantation between two 
different individuals (allotransplantation) would lead to graft rejection.  For this reason, 
Murray chose to perform his first procedure with identical twins.  Since the first 
transplant performed by Murray, extensive research has been performed to elucidate the 
mechanisms of rejection, leading to the identification of the Major Histocompatability 
Complex (MHC) loci, which in humans are the Human Leukocyte Antigen (HLA).  The 
HLA genes are highly polymorphic and encode MHC molecules that allow antigen 
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presenting cells (APCs) to display fragments of antigens to the immune system.  The 
greater number of differences between the donor and recipient at the HLA loci, the 
greater the probability of rejection is (Nankivell & Alexander, 2010).  An overview on 
MHC and HLA is provided in the transplantation and rejection section.  
Since the beginning of transplantation, the ultimate goal has been to prevent 
rejection.  Attempts to prevent rejection with immunosuppressive drugs began in the late 
1950’s to early 1960’s.  At that time azathioprine (anti-proliferative agent) and 
corticosteroids were the main therapeutics used and acute rejection was an ordinary 
occurrence (Murray, Merrill, Harrison, Wilson, & Dammin, 1963; Nankivell & 
Alexander, 2010).  In the early 1980’s, a major breakthrough came via availability of 
cyclosporine and the OKT3 monoclonal antibody (anti-CD3) which improved one-year 
survival of renal allografts from 60 percent to over 80 percent.  Since that time, there 
have been enhancements in immunosuppressive agents that have dramatically increased 
one year survival rates (Pascual, Theruvath, Kawai, Tolkoff-Rubin, & Cosimi, 2002).   
The current clinical immunosuppressive regimens in the United States includes a 
triple drug therapy of corticosteroids (e.g. Prednisone), tacrolimus, and MMF/MPA 
(Mycophenolate mofetil/Mycophenolic acid) as maintenance therapy (Matas et al., 2013).  
From the 2011 OPTN/SRTR reports, tacrolimus has replaced cyclosporine as the main 
calcineurin inhibitor used and MMF acts as the main anti-proliferative agent.  The 
rationale is to target multiple layers of a complex immune response that may activate 
lymphocytes and cause a rejection crisis.  Corticosteroids are used to suppress the 
immune system systemically and non-specifically.  Calcineurin inhibitors are used to 
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prevent the expansion of T cells and anti-proliferative agents prevent DNA synthesis and 
division of T cells (Abboudi & Macphee, 2012).  Over the past couple of decades, these 
new immunosuppressive drugs have improved one-year survival of kidney allografts to 
over 90 percent (Lamb, Lodhi, & Meier-Kriesche, 2011).  Preventing acute rejection 
(rejection within 1 year of transplant) was a major problem that has largely been 
overcome with more effective immunosuppression protocols.  Until recently, most 
research has been focused on preventing acute rejection.  While this issue has been 
resolved in the vast majority of cases, the maintenance and long term survival of the 
kidney allograft remains a problem (Gaston, 2011).  It was thought by many that solving 
the issue of acute rejection would translate into decreased late allograft loss (Pascual et 
al., 2002).  From 1989 until 2008 the 5 year survival rate of kidney allografts has 
remained at approximately 80% (Lamb et al., 2011).  Acceptance of the donor kidney has 
been achieved in the induction phase of tolerance (first year), but chronic rejection 
(rejection after 3 years of transplant acceptance) remains an issue.  Kidney transplants 
from deceased donors have a 5 year survival rate of approximately only 50% relative to 
those receiving a kidney from a living donor (Leventhal, Miller, Abecassis, Tollerud, & 
Ildstad, 2013).  Despite recent advances in immunosuppressive therapies, the half-life of 
renal allografts is still only about 8 years (Janeway, Murphy, Travers, & Walport, 2008).  
Therefore, most recipients of renal allografts will ultimately reject their grafts.  
Even with lifelong acceptance of allografts, recipients of transplants require the 
use of immunosuppressants for the remainder of their lives to prevent graft rejection.  
With the lifelong use of immunosuppression comes a variety of side effects, including 
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infection, cancer, diabetes, heart disease, and nephrotoxicity.  Even with 
immunosuppression to maintain acceptance of the graft, there is often ultimately kidney 
graft loss (Scandling, Busque, Shizuru, Engleman, & Strober, 2011).  There are many 
researchers attempting to find new immunosuppressive medications that have fewer side 
effects and still prevent graft rejection.  The triple drug immunosuppression was designed 
to have greater potency in accepting allografts, while reducing some of the side effects.  
The ideal clinical goal is to prevent rejection without the use of immunosuppression.  
This would require a development of lifelong tolerance and eliminate or substantially 
reduce the deleterious side effects.  In order to devise a protocol that will give patients 
lifelong tolerance, a more extensive understanding of the basis of transplant rejection is 
necessary.   
 
BACKGROUND 
Transplantation and Rejection  
 Rejection of transplanted organs is caused by the immune system’s response to 
alloantigens on a donor graft.  An alloantigen is a protein or a carbohydrate that is 
different between individuals of the same species.  Due to this variance, the recipient may 
see these antigens as foreign and mount an immune response.  The major 
histocompatibility complex (MHC) molecules are highly polymorphic; most rejection is 
caused by differences in the MHC class I antigens.  However, even with perfect 
matching, rejection may occur because of genetic differences at the minor 
histocompatibility level.  While genetic differences at the minor loci provide a slower 
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rejection, it is still ultimately rejection.  Unless patients are identical twins, the 
differences at major and minor histocompatibility complexes create the necessity for 
immunosuppression to avoid rejection (Janeway et al., 2008). 
 The MHC is also known as the HLA in humans and the Swine Leukocyte Antigen 
(SLA) in pigs.  T cells encounter antigens as peptides displayed by the two major MHC 
molecules, MHC class I and MHC class II.  MHC I and MHC II glycoproteins present 
peptides on the surface of their cells so the immune system can mount a response if 
needed.  MHC I presents endogenous antigens such as viruses, are recognized by CD8 
cytotoxic T lymphocytes (CTLs); all nucleated cells express MHC I.  On the other hand, 
MHC II presents exogenous antigens such as bacteria.  These antigens are then 
recognized by CD4 helper T cells.  Only APCs (dendritic cells, macrophages, and B 
cells) can express MHC II.  MHC genes are polygenic, meaning there are several genes 
for class I and class II molecules for each individual.  To further complicate matters, the 
MHC molecules are the most polymorphic genes known.  For example, for HLA-B there 
are more than 700 alleles.  Due to the number of alleles seen in the population, most 
individuals are heterozygous at the MHC loci.  Each person expresses different MHC I 
and MHC II molecules and has various haplotype combinations.  The variance in 
individuals provides for alloreactivity and rejection in transplants (Janeway et al., 2008). 
The current problem is the long term survival of grafts.  The rejection is seen to 
occur via two major pathways.  One path is by direct presentation of donor antigens by 
donor APCs that results in a rejection crisis.  The APCs present antigens to lymph nodes, 
T cells expand and then attack the donor graft.  In the indirect pathway, host APCs 
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present donor antigens leading to rejection.  The alloantigens presented are from the 
disparate MHC molecules on the donor graft (Janeway et al., 2008).   
 Another problem seen in transplantation, specifically with bone marrow, is graft-
versus-host disease (GVHD).  The mismatch of class I MHC or class II MHC antigens 
cause the reaction.  The minor histocompatibility complex also can create the reaction, 
although usually less severe.  In this process, T cells from the donor develop and mature; 
these T cells recognize the recipient as foreign using the recipient’s immune system.  One 
interesting phenomenon related to GVHD is graft vs. leukemia (GVL), which can occur 
in leukemia patients that receive bone marrow transplantation.  In this case, the donor 
bone marrow kills off the leukemic cells.  In bone marrow transplantation for the 
treatment of leukemia, the goal is to reduce GVHD effects while enhancing the GVL 
effects (Janeway et al., 2008).  GVHD and rejection have greater complexities that must 
be studied further to advance transplantation.  At the same time, advancements in the 
understanding of these two processes have allowed for improvements in protocols to 
achieve lifelong tolerance. 
   
Tolerance 
 In transplantation, the goal is to prevent rejection, and with bone marrow, GVHD 
as well.  To prevent these outcomes, the major goal since the first induction of tolerance 
in mice in 1953 has been to establish tolerance for organ transplants.  For a long time 
tolerance was simply defined as the “specific absence of an immune response”.  Over the 
past sixty years the field of transplantation biology, and more specifically tolerance, has 
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rapidly evolved.  Much is now known about a positive regulatory immunological 
response involved in tolerance.  Due to the complicated nature of tolerance, the concept is 
now referred as “operational transplant tolerance”.  This is defined as “the specific 
absence of a destructive immune response to a transplanted tissue in the absence of 
immunosuppression” (Sachs, 2011).  The definition includes the involvement of 
regulatory mechanisms in tolerance and is a state where patients accept transplants 
without any immunosuppression.  Included in the definition is that the recipient has a 
functional immune system (Bishop et al., 2011).   
 Recent achievements include the use of bone marrow or stem cell transplantation 
before kidney transplantation to induce tolerance in HLA-matched and HLA- 
mismatched humans.  Mixed hematopoietic chimerism has been used in HLA-matched 
and mismatched humans to achieve tolerance via a non-myeloablative regimen.  The 
mixed chimerism approach allows the donor cells to take up most of the bone marrow of 
the recipient, but not deplete the recipient bone marrow.  This allows the patient to 
become tolerant to donor while retaining self.  In addition, the non-myeloblative 
approach allows for more widespread applicability in the field of transplantation due to 
the sub lethal amounts of radiation that are necessary.  Non-myeloalative regimens are of 
reduced intensity and do not completely deplete a recipient’s immune system before 
transplantation.  This allows for bone marrow transplantation in the absence of 
malignancy.  Previously, the ablative approach would only allow for this approach in 
patients with malignant diseases (Leventhal et al., 2013).  The first approach to using a 
non-myeloablative  mixed chimerism strategy employed a protocol originally studied in 
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mice and primates, that was recently transitioned  to the clinic at Massachusetts General 
Hospital (MGH) ("A step closer to effective transplant tolerance?," 2012).  The first six 
patients in the trial received bone marrow and kidneys from HLA identical siblings and 
became tolerant to their renal transplant via a mixed chimera approach (Fudaba et al., 
2006).  Studies performed at Northwestern and Stanford using different, non-lethal 
preparatory regimens have similarly led to transplantation tolerance in conditioned HLA-
matched individuals.  At MGH, the next trial involved HLA-mismatched transplants and 
four of the first five patients became tolerant (Kawai et al., 2008).  Over two trials, seven 
of ten patients have been weaned off immunosuppressants without signs of rejection.  
Thus, this protocol provides promise for the future of tolerance (Kawai, Cosimi, & Sachs, 
2011).       
 A further understanding of tolerance will also lead to a greater insight of the 
immune system’s self/non-self discrimination mechanisms.  In addition, with greater 
understanding of tolerance there is a chance to provide patients with transplants while 
avoiding complications and adverse effects associated with immunosuppressants for life.  
Currently, all clinical trials that are able to induce renal allograft tolerance are from living 
donors and the recipient must undergo a conditioning protocol a few days prior to 
transplant.  The goal is to find a course of treatment where tolerance can be induced after 
transplant, so that cadaver donors can be used (Sachs, 2011).  There are protocols 
currently under investigation that use a delayed tolerance protocol.  This will allow a 
patient to become tolerant after a transplant (Kawai et al., 2011).  By defining the 
mechanisms underlying tolerance and the interplay of various components of the immune 
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system, tolerance strategies could be improved and offered to a larger number of 
transplant patients. 
 
Mechanisms of Tolerance  
 Tolerance involves both central and peripheral mechanisms.  While historically 
there has been a distinction between central (thymic-dependent) and peripheral 
(extrathymic) mechanisms, there seems to be much less of a distinction between the two 
now.  Central and peripheral mechanisms work together to induce and maintain tolerance.  
Using the mixed chimerism protocol discussed above, initial bone marrow transplantation 
allows for proliferation of donor stem cells in a host bone marrow compartment.  With 
current conditioning, the host bone marrow is depleted with a non-myeloablative 
protocol.  After populating the host compartment, the donor cells along with host cells 
produce a mixed chimera environment in the recipient bone marrow.  APCs will then 
present these cells from the bone marrow to the thymus to attain tolerance by elimination 
of host and donor reactive T cells.  This is achieved via negative selection to discriminate 
between self and non-self.   The thymus sees the presented donor and host cells as self 
and will delete T cells that will react against these cells.  Thus, the donor and recipient 
are seen as self by the immune system.  While this is the basis for central tolerance, there 
are undoubtedly cells that escape the thymus and thus peripheral tolerance mechanisms 
are necessary.  Maintenance of tolerance is believed to be produced by regulatory cells 
within the kidney graft and in the periphery which will be discussed later (Al-Adra & 
Anderson, 2011).   
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There are thought to be four main mechanisms of tolerance that work together in 
induction and maintenance phases (Al-Adra & Anderson, 2011).  While these 
mechanisms also can apply to B cell tolerance, the focus in this thesis will be on T cells 
because of their pivotal role in transplant rejection. 
 
Deletional Tolerance  
 The immune system’s major mechanism for establishing tolerance to self occurs 
in the thymus.  During development, thymic epithelial cells present self-antigens to T cell 
receptors, so that T cells can play the important role of discriminating between self and 
non-self.  Thymocytes and APC progenitors are transported from the bone marrow to the 
thymus to mature.  In the thymus, thymocytes can become double negative (CD3
+
CD4
-
CD8
-
); CD3 is a marker for all T cells, CD4 for helper and regulatory T cells (Tregs), and 
CD8 for cytotoxic T lymphocyte.  APCs also undergo maturation in the thymus.  
Thymocytes are evaluated in the thymus in a series of steps.  The double negative T cells 
first may rearrange their T cell receptor (TCR) and become double positive cells 
(CD3
+
CD4
+
CD8
+
).  Through a series of low intermediate affinity interactions between 
the rearranged T cell receptors on the thymocytes and self MHC/peptides on the thymic 
epithelial cells, only the immature thymocytes with a functional TCR will be selected 
(positive selection).  Positively selected thymocytes then mature to either the T helper 
phenotype (CD3
+
CD4
+
CD8
-
) or cytotoxic T cell phenotype (CD3
+
CD4
-
CD8
+
).   Negative 
selection ensures the elimination of autoreactive T-cell clones, by deleting T-cell 
populations that bind T cell receptors with high affinity.  After positive and negative 
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selection in the thymus, only T cells with low intermediate binding affinity will be 
released into the periphery (Sykes, 2007).    
 In mixed chimeras, donor and recipient thymocytes and APC progenitors travel 
from the bone marrow to the thymus and undergo the process of selection and maturation 
as described above.  The difference in mixed chimeras as compared to normal immune 
system development is in the process of positive selection; in this situation selection 
occurs in the context of host thymic epithelial cells.  The MHC is of host origin and will 
select for donor and recipient single positive T cells of appropriate low intermediate 
affinity interactions.  Donor and recipient single or double positive T cells that interact 
with high affinity to donor or recipient APCs or thymic epithelial cells presenting self 
MHC/peptide will be deleted by negative selection.  Thus, the only T cells allowed out of 
the thymus will be cells that are tolerant of both donor and host (Sykes, 2007). 
 Mature T cells can also be deleted in the periphery by various mechanisms if they 
escape central deletion.  One such mechanism is deletion of tissue specific cytotoxic 
lymphocytes in the lymph nodes via self-antigen cross presentation by dendritic cells.  In 
addition, cytotoxic T cells may be deleted in the periphery because of exhaustion.  
Exhaustion is repeated exposure to an immense antigen load that results in CD8 cell 
deletion (Sykes, 2007).  Although deletion is the major mechanism to inducing tolerance, 
there are many other mechanisms that play a role in inducing and maintaining tolerance. 
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Anergy 
 Anergy describes T cells incapable of expanding and producing cytokines in 
response to antigens that they can identify.  Mature T cells will undergo activation if they 
are stimulated by an antigen they can recognize.  In order for T cells to be activated they 
must be stimulated at both the T cell receptor and co-stimulatory receptors.  Without 
stimulation of the co-stimulatory molecules, the T cell will remain in a quiescent, anergic 
state; this observation has inspired a great deal of research into methods for blocking co-
stimulation and subsequent T cell anergy.  In some cases, anergy can also occur if T cells 
encounter low affinity MHC/peptide complexes on APCs.  In tolerogenic states, specific 
APCs have been shown to induce anergy by producing cytokines that suppress T cell 
activity.  Anergic T cells may suppress other cells, including Tregs.  Tregs can function 
to put cells into an anergic state.  Anergy can occur in the periphery and intrathymically 
through interaction of T cell receptors with thymic stromal cells or hematopoietic cells 
(Sykes, 2007).   
 
Regulation (Suppression) 
 The immune system can play an active role in regulating itself and T cell 
reactivity through regulation and suppression.  There has been a great deal of research 
devoted to elucidating this mechanism for maintaining tolerance.  This work has revealed 
a great deal about the intricacies of the suppressive and regulatory mechanisms of the 
immune system, especially as they relate to transplantation biology and tolerance.  Some 
of these mechanisms include the production of inhibitory cytokines and killing of APCs 
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by cytotoxic T lymphocytes.  Also, the thymus can produce Tregs that play a role in 
inducing and maintaining tolerance.  In short, the Tregs play a role in suppressing a 
rejection of donor graft when tolerance is achieved.  Recent work in this field has 
demonstrated the importance of this cell subtype in maintaining tolerance.  The 
suppressive functions of these cells include the secretion of cytokines and inhibition of 
the immune responses towards donor grafts.  There will be a more detailed discussion of 
Tregs and their applicability to the clinic later in this thesis.  Due to their suppressive 
nature, Tregs have been studied extensively in order to find a way to use them as a tool to 
achieve tolerance in transplantation (Sykes, 2007).   
 
Ignorance  
In some situations, recipient cells may also just ignore the donor graft antigens.  
Receptors are able to identify donor antigens, but may fail to mount an immune response.  
A couple of explanations for this observation are that (i) T cells are not able to expand 
and transport to the tissue with the antigen and (ii) there have been certain 
‘nonprofessional APCs’ that are unable to activate T cells (Sykes, 2007).  In this state 
tolerance can be achieved, but is in a metastable state.  If  a more immunogenic 
environment is provided, such as by adding IL-2, rejection occurs (Li, Strom, Turka, & 
Wells, 2001).  Further knowledge of the interplay between all these mechanisms will 
allow for attaining the ultimate goal of achieving lifelong tolerance in transplant patients.  
The small animal model provides an excellent opportunity to attain a more complex 
understanding of the mechanisms and interactions involved in tolerance. 
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Small Animal Model- Mouse  
 In the past three decades studies in rodent models have facilitated progress in 
immunology and biology of transplantation.  The small animal models have allowed for 
experimentation to further the understanding of tolerance.  Mice provide a model with 
many genetic similarities to humans.  Before experimentation is done in large animals 
and then humans, the mouse model provides a simple model to determine if these 
experiments will be feasible (Russell, 2002).  The genetic similarities allow for 
manipulation of genes and other components to mimic certain human conditions and 
human diseases.  In both species, the paths that control normal and pathological 
conditions are mostly preserved (Rivera & Tessarollo, 2008).  The close relationship to 
humans, ease of manipulation, and abundance of small animal models provides great 
advantages for research.  
 Studies in rodents have progressed dramatically with outstanding results.  The 
first studies to induce tolerance with mixed chimerism in mice used lethal irradiation of 
the recipient mouse.  The donor bone marrow and recipient’s T cell depletion resulted in 
tolerance and mixed chimeras for the remainder of the mice’s lives.  An initial study of 
hematologic malignancies in mice to achieve the graft versus leukemia effects without 
graft versus host disease using mixed chimerism and donor leukocyte infusion has been 
modified and transferred to the clinic to treat patients with lymphomas and leukemia 
(Fudaba et al., 2006; Mapara, Kim, Marx, & Sykes, 2003; Mapara et al., 2002).  While 
tolerance was achieved, a conditioning regimen in humans that involves lethal irradiation 
and chemotherapy is toxic and could only be used in malignant cases.  Thus, a less toxic 
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protocol was necessary for organ transplantation in non-malignant cases.  Conditioning 
needed to be enough to kill alloreactive T cells centrally in the thymus and in the 
periphery, while trying to reduce the side effects of irradiation.  In a mouse study, a low 
amount of total body irradiation (300 rads) was used to eradicate the T cells in the 
periphery; thymic irradiation (700 rads) was added to rid the thymus of the reactive T 
cells centrally, followed by donor bone marrow infusion and short term treatment with T 
cell depleting antibodies.  The result was tolerance via central deletion by generating 
mixed chimerism in MHC mismatched mice.  In an attempt to separate GVL from 
GVHD, successful protocols have been devised for HLA-matched patients with multiple 
myeloma and afterword for HLA-mismatched patients without other life-threatening 
diseases (Sachs, Sykes, Kawai, & Cosimi, 2011). 
 While there have been numerous studies displaying tolerance in mouse models, 
many of these protocols have not been successfully transferred to large animal models 
and humans.  Large animals and humans have greater complexities that cannot be 
recreated in a mouse model.  This is especially the case when one considers the immune 
system and transplant tolerance.  A limited number of tolerance inducing protocols have 
been transferred from rodents to nonhuman primates and even fewer to humans.  One 
possible reason for this is the T memory response that is seen in nonhuman primates, but 
not rodents.  The T memory responses are thought to be the cause of resistance to 
tolerance by mixed chimerism (Kawai et al., 2011).  Thus, it is evident that there are 
major differences in the biology of mice, large animals, and nonhuman primates.  The 
developmental and genetic differences of these animals provides for significant variation 
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in the way their immune systems function, as well as how their bodies respond to drugs 
(Sachs et al., 2011).  Therefore, experiments performed in small animal models need to 
be reproduced in the large animal models before being applied to humans.  
   
Large Animal models 
 Before protocols can be applied in the clinic, they should be demonstrated in large 
animal models, such as miniature swine and nonhuman primates, to test protocols for 
safety and efficacy.  Using these models, it is possible to refine protocols and identify 
problems that may affect patients.  Miniature swine have many of the same 
immunological properties and genetics as humans.  Nonhuman primates are even closer 
genetically with even more similar immune interactions.  One biological difference that 
has been seen in large animals and not in rodents is the expression of class II antigens 
continuously on vascular endothelium of organs.  This is only one difference that has 
been seen in swine and humans as compared to rodents that may play a role in 
determining successful transplants (Yamada et al., 1997). 
With the mouse model as a basis for preliminary studies in 1995, our lab used a 
non-myeloablative protocol to induce renal allograft tolerance in cynomolgous monkeys.  
Mixed chimerism and tolerance was achieved in MHC-mismatched nonhuman primates.  
The conditioning regimen included anti-thymocyte globulin as a T-cell depleting agent, 
total body irradiation of 300 or 150 rads, thymic irradiation of 700 rads, 30 days of 
Cyclosporine A and donor bone marrow infusion.  In the study, mixed chimerism was 
observed, as well as long term renal allograft tolerance.  The monkeys became tolerant, 
17 
 
were weaned of immunosuppression, and accepted the transplanted grafts indefinitely 
(Kawai et al., 1995). 
 In addition, a similar conditioning and mixed chimerism approach has been used 
in the miniature swine model in our laboratory.  Miniature swine were conditioned with a 
non-myeloablative protocol that included whole body irradiation, thymic irradiation, 
CD3-immunotoxin treatment to reduce T cells, 30 days of Cyclosporine A, and infusion 
of donor bone marrow or peripheral blood stem cells.  These SLA matched recipients 
developed mixed chimerism and long-term tolerance.  This was the first time tolerance 
was successfully induced via mixed chimerism in a swine model (Huang et al., 2000). 
 Previous work from this lab has also demonstrated that the thymus plays an 
essential role in the induction of transplantation tolerance.  In class I mismatched swine, 
thymectomized swine displayed rejection of their transplants, while those with an intact 
thymus were shown to induce and maintain tolerance.  This supports the theory of the 
thymus and central deletion being vital to inducing tolerance.  While central tolerance via 
the thymus is critical, there are also peripheral mechanisms that work in synergy with the 
central mechanisms (Yamada et al., 1997).  In another study of MHC I disparate swine, 
the thymus’ presence was shown to be critical in inducing tolerance until day 42.  
Animals that underwent thymectomy on days +8 and +21 post transplant did not show 
stable graft function, while animals that where thymectomized on POD 42 or later 
became uniformly tolerant.  Thus, the thymus is not required to maintain tolerance, but is 
required to induce central and peripheral tolerance (Vagefi et al., 2004).   
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 Our lab has developed a tolerant renal transplant model in Class I mismatched 
miniature swine.  By using Cyclosporine A for a twelve day period at 10-13 mg/kg daily, 
long term tolerance was achieved in 100% of two-haplotype class I mismatched, class II 
matched, renal allografts (for example (class I
dd
 to class I
gg
)).  Kidney transplants without 
Cyclosporine A in this same model were uniformly rejected by two weeks.  After 
tolerance was achieved, systemic tolerance was tested by removing the primary graft and 
replacing the graft with a second donor-matched kidney graft.  Tolerance was confirmed 
as the swine were able to accept the second kidney without immunosuppression.  
Cyclosporine A is used in this model to suppress helper T cells that are class I specific. 
Consistent with this, graft acceptors do not class switch from IgM to IgG antibody 
production due to the absence of T helper cells (Rosengard et al., 1992).  
 In MHC class I mismatches, the indirect pathway of antigen presentation must be 
involved because MHC I antigens have to be presented by host MHC II.  Cyclosporine A 
is effective in preventing the indirect pathway for antigen presentation.  Fully 
mismatched transplants refers to disparities at both the MHC I and MHC II loci.  Use of 
Cyclosporine A did prolong survival in this model, but was not able to maintain tolerance 
in fully-mismatched barriers.  The fully mismatched transplants invoke the indirect and 
direct pathways of antigen presentation.  Thus, Cyclosporine A is less effective when the 
direct and indirect pathways of allorecognition are involved.  In this model, regulatory 
mechanisms have been seen to induce and maintain tolerance (Rosengard et al., 1992). 
 Our lab was able to induce tolerance in miniature swine across full-MHC barriers.  
This was done by using 0.15-0.30 mg/kg daily of tacrolimus (FK 506) for 12 days to 
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induce tolerance across two-haplotype fully mismatched MHC barriers.  Examples of this 
would be a SLA
dd  
(Class I
dd
 Class II
dd
) kidney transplanted into a SLA
cc  
(Class I
cc
 Class 
II
cc
) animal.  In this model, analysis indicated the presence of regulatory mechanisms and 
cells maintaining tolerance (Utsugi et al., 2001).  Currently, we use these two models in 
MHC class I mismatched and MHC fully mismatched experimental transplants. 
 
Why our model? 
 The 12-day course of Cyclosporine A tolerance model has been extensively used 
to study the mechanisms of transplantation tolerance in large animals.  In a previous 
study, we isolated peripheral blood lymphocytes (PBL) from tolerant animals and primed 
them in vitro with donor antigen.  Using cell-mediated lympholysis assays (CML), these 
primed PBLs were added to cultures of naïve recipient-matched PBLs stimulated with 
donor-matched targets.  The in vitro results showed suppression of anti-donor cytotoxic T 
lymphocytes by PBLs from the tolerant animals.  Conversely, when donor primed 
tolerant PBLs were added to cultures containing naïve recipient-matched PBLs and third 
party target cells, suppression was not observed.  Similarly, PBLs from naïve animals 
primed with donor Ag that were added to cultures of PBLs from tolerant animals 
stimulated with third-party antigen did not suppress proliferation.  Additionally, the 
suppression was dose dependent, sensitive to radiation, needed cell-to-cell contact, and 
was not reversed by administration of exogenous IL-2 (Ierino, Yamada, Hatch, Rembert, 
& Sachs, 1999; Ierino, Yamada, Lorf, Arn, & Sachs, 1998).  These studies provide data 
in support of regulatory mechanisms and peripheral regulatory cells being essential in 
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inducing and maintaining tolerance to renal allografts.  At the same time, these studies 
only provided in vitro evidence for the role of regulation in tolerance.  In our study, we 
investigated the role of Tregs in an in vivo model. 
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OBJECTIVES 
The objective of this study is to provide direct evidence of role of Tregs in transplantation 
tolerance using an adoptive transfer model. 
 
Specifically, we will determine the interactions involved in maintenance of tolerance.  
We hypothesize that T regulatory cells are present in the kidney graft and in the 
periphery.  We hypothesize that the Tregs interact with the peripheral T cells and are vital 
in maintaining tolerance through suppression. 
Using this as our basis we want to:   
 Test if a large dose of tolerant cells can have an effect on graft survival. 
 Test if long-term tolerated kidney allografts have immunoregulatory 
effects. 
 Test if we can adoptively transfer tolerance with donor-matched cells and 
kidneys from long-term tolerant animals. 
 
We hope these studies will display the importance of Tregs in the induction and 
maintenance of tolerance in an in vivo animal model. 
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MATERIALS AND METHODS 
Animals 
MHC inbred MGH-miniature swine provides the advantage of studying transplantation 
biology in a genetically defined model that can mimic transplantation in humans.  MHC 
homozygous and intra-MHC recombinant haplotypes allow us to study that the class I 
and/or class II loci play in transplantation.  This is the only large animal model that can 
select for MHC I and MHC II genes in order to study their role in transplant rejection 
(Pennington, Lunney, & Sachs, 1981; Sachs et al., 1976).  Swine are one of the only 
species where inbreeding can allow for genetic experiments in a large animal model.  
This is due to sexual maturity being at 6 months of age, a large litter size of about 3-10 
offspring, and a short gestation time of 3 months.  Due to these circumstances, specific 
MHC lines could be made in a short amount of time.  Being the only MHC defined large 
animal model allows us to study MHC matching’s effects on tolerance and rejection.  
There are currently three homozygous SLA haplotypes and five recombinant haplotypes.  
See Figure 1 for the origin of haplotypes.  Every swine line varies in minor 
histocompatibility loci, which is usually the case in human transplantation.  Thus, most of 
the transplantation combinations seen in humans can be reproduced in this model.  
Transplants within a MHC homozygous herd can mimic HLA identical siblings, 
transplants between herds can represent non-matched siblings, and transplants between 
heterozygotes can represent one haplotype mismatched siblings.  These are only 
examples, but use of these animals clearly displays a tremendous advantage in studying 
transplantation biology for humans.   
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The SLA
dd 
animals were selected for further inbreeding to create a fully inbred 
line and have reached a coefficient of inbreeding of > 94% (Mezrich et al., 2003).  These 
animals have allowed for adoptive transfer protocols for the first time in a large animal 
model by reducing minor histocompatibility differences that may cause rejection.   
 
 
 
Figure 1: The origin of haplotypes of MGH inbred miniature swine 
(Figure taken from Vagefi et al., 2004)  
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Donor animals used in our study were SLA
gg 
(Class I
c
/II
d
) partially inbred MGH 
miniature swine.  Recipient animals were 4-10 months of age from the inbred line of 
SLA
dd 
(Class I
d
/II
d
) MGH miniature swine that were chosen to reduce minor antigen 
differences.   
 
Experimental Groups 
 SLA
dd
 animals received two-haplotype class I mismatched kidneys (SLA
gg
) with a 
12-day course of Cyclosporine A to attain blood levels of 400-800 ng/ml (CyA; 
Sandimmune, generously provided by Novartis Pharmacutical Corporation, East 
Hanover, NJ) (Yamada et al., 1997).  All animals became long-term tolerant (LTT) 
animals.  This was shown through acceptance of the first renal graft with stable renal 
function for at least 90 days.  These long-term tolerant animals were then used as 
adoptive transfer donors for naïve SLA
dd
 recipients in Groups A-E.  With the exception 
of one animal in Group A, naïve adoptive-transfer recipients were treated with 150 rads 
of whole body irradiation (WBI) one-day before receiving class I MHC-mismatched 
kidney grafts from naïve SLA
gg 
pigs.  Group A animals received the naïve SLA
gg 
kidney 
grafts and peripheral blood mononuclear cells (PBMCs) from long-term tolerant animals.  
Group B animals received kidney grafts from long-term tolerant animals.  Group C 
animals received kidney grafts from long-term tolerant animals that were treated with 
donor-specific transfusion as described below.  Group D animals received kidney grafts 
from long-term tolerant animals without donor-specific transfusion.  Group E animals 
received PBMCs and kidney grafts from long-term tolerant animals with donor-specific 
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transfusion.  Additionally, the long-term tolerant SLA
dd 
pigs that were adoptive transfer 
donors for the animals in groups A-E received a second class I MHC-mismatched graft 
from a naïve SLA
gg
 animal on the same day as the nephrectomy of the tolerated graft.  
There were three recipients of adoptive transfer in most of the animal group (A,C,D,E) 
and 6 in group B.  Table 1 shows the experimental groups that were used. 
 
 
 
 
 
 
 
Surgery 
 Details of the surgical procedures have been described elsewhere (Rosengard et 
al., 1992; Yamada et al., 1997).  Briefly, both native kidneys were removed on the day of 
the primary kidney transplant.  Donor kidneys were perfused with Eurocolins and 
immediately anastomosed to the nephrectomized recipients’ aorta and vena cava.  The 
ureter was anastomosed to the recipient bladder.  For secondary transplantation, the 
kidney was transplanted using the same procedure at the same site or 1 cm below the 
Table 1: Treatment to recipient (SLA
dd
) of naïve kidney (SLA
gg
). 
DST = donor-specific transfusion; LTT = long-term tolerant; PBMCs = peripheral blood 
mononuclear cells; WBI = whole body irradiation  (Table taken from Okumi et al., 2013.  
Permission given by Wiley Online Library to use Table.) 
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primary graft anastomoses.  Indwelling central venous catheters were place surgically in 
the external and internal jugular veins of recipient animals to facilitate frequent blood 
sampling and the administration of fluid, drugs, blood, and PBMCs. 
 
Donor-Specific Transfusion (DST)  
 SLA
dd 
LTT animals that served as adoptive transfer donors to groups B, C, and E 
were given an intravenous transfusion of 10 ml/kg (body weight) non-irradiated SLA
gg
 
whole blood one week prior to leukapheresis.  The dose of blood for the DST was based 
upon rodent allotransplantation models (Bushell, Karim, Kingsley, & Wood, 2003; Niimi 
et al., 2000). 
 
Transfer of Peripheral Blood Mononuclear Cells (PBMCs) 
 A total of 2.5x10
9
 PBMCs/kg(recipient body weight) were collected by 
leukapheresis using a COBE Spectra machine (COBE BCT Inc., Lakewood, Colorado, 
USA) from LTT animals and were then infused intravenously to recipient in groups A, B, 
and E one day prior to transplantation.  The appropriate number of tolerant PBMCs was 
based on studies of the adoptive transfer of tolerant spleen cells in mouse models 
(Bemelman, Honey, Adams, Cobbold, & Waldmann, 1998; Qin et al., 1993). 
 
Transfer of Long-Term Tolerated Kidney Allografts 
 Long-term tolerated SLA
gg 
kidney grafts were harvested from LTT SLA
dd 
animals 
and transplanted into SLA
dd
 recipients in groups C, D, and E at the same time as the 
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naïve SLA
gg
 kidney grafts.  Following donation of the tolerated kidney allograft, LTT 
animals received a second naïve kidney graft from a SLA
gg 
animal. 
 
Histology of Long-Term Tolerated Kidney Allografts 
 Immunohistochemical analysis of frozen sections of long-term tolerated kidney 
grafts was performed using the standard avidin-biotin horseradish-peroxidase complex 
(ABC) technique to detect the phenotype of graft infiltrating cells.  For the detection of 
proliferating cell nuclear antigen (PCNA), sections of 10% buffered formalin-fixed, 
paraffin-embedded tissue blocks were stained using the ABC technique (Shimizu, 
Yamada, Meehan, Sachs, & Colvin, 2000). 
 
Quantitative Analysis of Tregs in kidney grafts 
 Two LTT kidneys and one rejected kidney from Group B were double stained for 
CD25 (FITC) and Foxp3 (Bio-PEAV) to assess the Treg cell population.  The percent of 
CD25 and Foxp3 double positive cells out of CD25 cells at 100x magnification were 
viewed with a standard deviation of ± 9. 
 
Monitoring of Rejection 
 Rejection of kidney grafts was monitored by plasma creatinine levels and by 
histological examination of kidney biopsies.  Renal open-wedge biopsies were performed 
through a flank incision.  Tissues were stained using hematoxylin-eosin and periodic 
acid-Schiff, and coded slides were examined by light microscopy by a pathologist so that 
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the analysis would be blinded.  Graft rejection was scored according to a standardized 
grading system of pathological specimens (Colvin, 1996). 
 
Preparation of Peripheral Blood Mononuclear Cells (PBMCs) 
 For the separation of PBMCs, freshly heparinized whole blood was diluted 1:2 
with Hank’s balanced salt solution (HBSS, Invitrogen) and the mononuclear cells were 
obtained by gradient centrifugation using Histopaque (Sigma).  The mononuclear cells 
were washed once with HBSS, and contaminating red cells were lysed with ammonium 
chloride potassium buffer (BioWhitaker).  Cells were then washed with HBSS and 
resuspended in tissue culture medium.  All cell suspensions were kept at 4°C until used in 
cellular assays.   
 
Cell-Mediated Lympholysis Assays 
 The procedure for CML assays has been described previously (Yamada et al., 
1997).  Briefly describing the assay, lymphocyte cultures containing 4x10
6 
responder and 
4x10
6 
stimulator PBLs (irradiated with 2,500 rads) were incubated for 6 days at 37° C in 
7.5% CO2 and 100% humidity.  Bulk cultures were harvested and effectors tested for 
cytotoxic activity on 
51
Cr (Perkin Elmer) labeled targets generated from lymphocytes 
stimulated for 24 hours with a 1:500 dilution of phytohemagglutinin (PHA, M-Form; 
Invitrogen) previously titrated to give optimal proliferation.  Effector cells were 
incubated for 5.5 hours with a negative control target (i.e., target PBL matched to the 
effectors) and targets matched to the stimulators which included donor-matched PBL 
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(SLA
gg
: Class I
cc
/Class II
dd
) and third party stimulators (SLA
aa
: Class I
aa
/Class II
aa
).  
Effector:Target ratios of 100:1, 50:1, 25:1, and 12.5:1 were tested.  Supernatants were 
harvested using the Skatron collection system (Skatron, Sterling, VA).  
51
Cr release was 
determined on a gamma counter.  The results were expressed as: 
% specific lysis = Experimental release (cpm) – spontaneous release (cpm) x 100% 
                              Maximum release (cpm) – spontaneous release (cpm) 
 
 
Co-Culture Assays 
 Peripheral regulatory mechanisms were investigated by in vitro co-culture assays 
(Ierino et al., 1999).  The primary culture was set up as in CML assays.  These primed 
cells were then harvested and rested overnight at 4°C.  The resulting effector cells were 
co-incubated with naïve SLA matched PBMCs and irradiated donor-type or third party 
PBMCs for an additional 5 days. 
 
Antibodies and Flow Cytometry 
 The presence of anti-donor class I (MHC class I
c
) IgM and IgG in the serum of 
recipient swine was detected by indirect flow cytometry Fluorescence-activated cell 
sorting (FACS) that was performed using a Becton Dickinson FACScan 
microfluorometer (Sunnyvale, CA) and recombinant SLA PBMCs to determine the SLA-
binding specificity of the antibody as described in a previous paper (Griesemer et al., 
2008). 
30 
 
RESULTS 
 
Adoptive transfer of a high-dose of tolerant cells had a minimal outcome on graft 
survival 
Infusion of cells from long-term tolerant animals was not enough to increase graft 
survival of naïve kidneys in a naïve recipient across a class I mismatch 
 We tested if adoptive transfer of a high or “mega”-dose of PBMCs (2.5x109 
unprimed PBMCs/recipient kg) from a long-term tolerant animal one day before kidney 
transplant could induce acceptance of a class I mismatched kidney in a naïve animal 
without any additional treatment (Group A, Table 1).  The kidney was rejected by day 7, 
which is similar to rejection of class I mismatched kidneys transplanted without 
immunosuppression (Giangrande et al., 1997).  The infusion of PBMCs from the tolerant 
animal did not increase the graft survival in the naïve recipient (Figure 3A).  Thus, other 
changes would be necessary in the recipient or adoptive donor in order to increase graft 
survival. 
 
Donor-specific transfusion increased the in vitro suppressive effects of Tregs from 
long-term tolerant pigs 
 We hypothesized that DST can increase the number and/or potency of Tregs in 
vivo in LTT animals (Abe et al., 2009; Bushell et al., 2003).  We thought that these Tregs 
from long-term tolerant animals given as a high-dose of PBMCs to naïve recipients could 
increase graft survival.  We first tested if donor-specific transfusion in a LTT animal 
would increase the suppression of the normal immunologic response to donor stimulation 
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in vitro using co-culture assays.  After administration of 800 mL (10mL/kg) of donor-
matched, non-irradiated whole blood to LTT animals, we measured plasma creatinine 
twice weekly to assess kidney function.  CML and co-culture assay was setup before the 
DST and 1 week after the DST. 
 In all of the animals, plasma creatinine was within the normal range before and 
after the DST, indicating that DST did not have an effect on kidney function.  More 
importantly, the inhibitory effects of Tregs increased after DST.  The anti-donor CTL 
was 16% and 20% (at 100:1 of E:T ratio) before DST, and was gone one week after DST 
(Figure 2A).  A co-culture assay showed cells from the long term tolerant animal primed 
by donor antigens suppressed the naïve cytotoxic T lymphocyte response against donor-
type cells 70% and 80% before the DST and completely after the DST (Figure 2B). 
 
The effect of donor-specific transfusion on regulatory cells in vivo was minimal 
 Group B included 6 LTT donors primed with DST 8 days before adoptive transfer 
of cells in order to increase the number and/or potency of Tregs.  Recipients also received 
150 rad of WBI in an effort to decrease precursor alloreactive T cells (Table 1, Group B).  
3 of the 6 recipients also received high-dose of PBMCs (2.5x10
9
 unprimed 
PBMCs/recipient kg) from a LTT animal one day before kidney transplantation.  The 3 
animals who received only 150 rads of WBI rejected their kidney grafts by day 9 (Figure 
3B red lines).  Therefore, the donor-specific transfusion by itself could not increase 
survival of kidney grafts.  Two of the three animals that received PBMCs from LTT 
animals rejected in a manner similar to those without PBMCs from LTT animals (Figure 
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3B red) or Group A animals.  The remaining animal had renal graft function until day 30, 
although creatinine levels fluctuated (Figure 3B green). 
 
Adoptive Transfer of long-term tolerated kidney allografts had immunoregulatory 
effects 
Histology showed Foxp3
+
/CD 25
+
 cells in the LTT kidneys 
 LTT kidneys in class I mismatched Cyclosporine A model showed focal 
mononuclear cell infiltrates around vessels (Figure 4A).  These cells have been shown to 
be CD4
+
/CD8
+ 
cells, while cells in rejection are only CD4
+
 (Giangrande et al., 1997).  
Due to previous findings of IL-10 in the kidney infiltrate of tolerant animals (Blancho et 
al., 1995), we saw if the infiltrate included Foxp3
+ 
Treg cells.  Tregs express the 
transcription factor Foxp3, which gives Tregs their suppressive abilities (Bishop et al., 
2011). 
 Most of the infiltrate from the LTT grafts were CD25
+ 
T cells (Figure 4B), but not 
PCNA positive (Figure 4c).  CD25 is displayed on alloactivated effector T cells and 
Tregs.  Additional cell-staining showed that one third of the infiltrate was also Foxp3
+
 
(Figure 4d) and that some of these Foxp3
+
 cells were also CD25
+ 
(Figure 4E).  These 
Foxp3
+
 CD25
+
 cells confirmed the presence of Tregs in the long-term tolerated kidney 
grafts in the adoptive transfer model.  Foxp3 is a transcription factor that is expressed 
exclusively in Tregs and not in activated effector T cells.  In addition, as a control 
samples were evaluated from the  class I mismatched kidney transplant recipient that 
rejected in a cellular manner (30-day survivor in Group B).  The kidney was stained with 
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anti-pig CD25 and Foxp3 antibodies (Figure 4F).  A large number of CD25 positive cells 
were found in the graft, but most were Foxp3 negative (red).  Phenotypic analysis of  the 
cell populations in the kidneys of the two LTT animals showed 45.8 ± 10.6% of CD25
+ 
cells also were Foxp3
+
, as compared to the 30 day survivor graft with 10.3 ± 6.2% of 
CD25
+ 
cells being Foxp3
+
.  
 
 
 
 
 
 
 
Figure 2: CML and co-culture CMLs demonstrated that DST in LTT animals 
increased suppression of the anti-donor response in vitro. CTL and co-culture CTL 
assays were set up 1 week before and 1 week after the DST. Recipient responses to donor 
stimulation are shown with solid lines and boxes; third party stimulation are shown with 
dotted lines and striped boxes. (A) While the anti-donor CTLs were 16% and 20%, 
respectively before the DST, there were no anti-donor CTL responses 1 week after the DST. 
(B) Cells from the LTT animal primed by donor antigens specifically suppressed the naïve 
CTL responses against donor-type cells 70% and 80%, respectively before the DST, and 
completely (red line with an arrow) after the DST. 
(Figure taken from Okumi et al., 2013.  Permission given by Wiley Online Library to use 
Figure.) 
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Long-term tolerated kidney grafts have regulatory effects 
 Using groups C and D, we evaluated if transfer of LTT kidneys with the graft 
infiltrate, including Tregs, would increase survival in naïve recipients.  Six SLA
dd 
animals 
were treated with 150 rads WBI one day before kidney transplant.  Each of these animals 
had a SLA
gg
 tolerant kidney from a LTT SLA
dd 
pig cotransplanted with a naïve SLA
gg 
kidney.  Three of the LTT donors were given donor-specific transfusion one week before 
transplant like Group B (Group C).  The other three donors were not given DST and 
made up Group D. 
  Two animals in Group C and two animals in Group D rejected grafts by 10 days 
post-transplant.  One pig in group C did maintain stable renal function for at least 50 days 
and lost the graft at day 73 (Figure 3C).  Graft life was decreased when adoptive transfer 
donors did not receive DST.  One animal in Group D had renal function for 46 days but it 
was unstable throughout (Figure 3D).  Kidney biopsies from the two recipients who had 
increased graft survival showed differences between the naïve kidney grafts and LTT 
kidney grafts.  Histology of kidney graft biopsies taken at day 22 post-transplant in the 73 
day Group C survivor is in Figures 5A and 5B.  At day 22 the naïve kidney graft was 
rejected (Figure 5A) and the LTT kidney graft had minimal cellular infiltrate (Figure 5B).  
This shows that pre-existing Foxp3
+
CD25
+
 cells in the kidney graft had a protective role.  
Moreover, although the naïve kidney graft was rejected, no anti-donor (SLA
gg
) class I 
IgG was seen in either graft.  Also, the CML for the 73 day survivor showed donor 
specific hyporesponsiveness at day 46, while the 46 day Group D survivor had a high 
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anti-donor CML response on day 36.  This data indicated that the tolerant kidney had a 
role in regulating the local and systemic immunologic responses. 
 
 
 
 
 
Figure 3: Plasma Creatinine levels of recipients of class I mismatched kidneys with 
various treatments. Plasma creatinine levels (mg/dL) of recipients of class I mismatched 
kidneys treated with (A) infusion of tolerant PBMCs alone (Group A), (B) DST and a 150 
rad WBI with/without from LTT animals (Group B), (C) transfer of tolerated kidney grafts 
from LTT animals treated with DST and a 150 rad WBI (Group C), (D) transfer tolerated 
kidney grafts from LTT animals with a 150 rad WBI, without DST (Group D) and (E) 
transfer of both PBMCs and tolerated kidneys from LTT animals treated with DST and a 
150 rad WBI (Group E). 
(Figure taken from Okumi et al., 2013.  Permission given by Wiley Online Library to use 
Figure.) 
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Inducing tolerance of naïve class I mismatched kidneys using adoptive transfer of 
donor-kidney matched cells and kidneys form long-term tolerant animals (Group E) 
 To determine if using DST-priming of donor and subsequent transfer of PBMCs 
with tolerated kidney grafts from LTT animals could increase kidney graft survival or 
induce tolerance in recipients that had 150 rads WBI (Group E), additional studies were 
done.  This protocol is detailed in Figure 6.  The three animals were co-transplanted with 
naïve and tolerated class I mismatched kidneys.  Two of three animals underwent 
graftectomy of the tolerant grafts from LTT donors to evaluate graft function of SLA
gg 
kidney grafts from naïve animals on days 76 and 107 respectively.  One animal out of the 
three rejected both grafts by day 28 (Figure 3E).  Histology of the naïve graft showed 
severe diffuse interstitial hemorrhages and mononuclear cell infiltrates (Figure 5C) on 
day 28.  Biopsies taken from the LTT graft showed diffuse mononuclear cell infiltrates 
and glomerular changes, but with mild interstitial hemorrhages (Figure 5D).  Like Groups 
C and D, the tolerated kidney graft’s pre-existing intra-graft passenger leukocytes may 
have played a protective role.  
 The other two animals maintained stable renal function, although there were brief 
spikes of creatinine (Figure 3E).  Histology of the naïve and LTT kidney grafts on day 60 
displayed minimal mononuclear cell infiltrates without chronic vasculopathy (Figure 5E 
and 5F).  To assess the function of the naïve SLA
gg 
kidney grafts, we removed the kidney 
grafts from the LTT animals on days 76 and 107 respectively.  Both animals were able to 
maintain normal kidney function with the naive kidney graft for over 90 additional days 
(Figure 3E) without histological evidence of rejection (Figure 5G).  The 2 animals 
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accepted class I MHC mismatched grafts long–term demonstrating that co-transplantation 
of cells and kidneys from tolerant animals can induce and maintain systemic tolerance in 
a large animal model.    
 CML assays showed donor-specific unresponsiveness in the two long term 
acceptors at 30 and 60 days post-transplant.  In addition, cells from the animals remained 
unresponsive to donor stimuli for 75 days after removing the LTT kidney graft (Figure 
7A).  Lastly, co-culture assays to test for regulatory mechanisms displayed 100% 
inhibition of naïve CTL response to donor antigens. 
 
 Figure 4: Histological analysis of representative long-term tolerated kidney 
allografts. (A) Minimal cell infiltrate was seen in the tolerated kidney graft (H&E, 
x200). (B) Several of the cells in the graft were CD25 positive (black arrows); (C) most 
cells were PCNA negative (x400). (D) Foxp3 positive cells, shown with arrows, were 
found in the tolerated kidney graft (x400). (E) Some cells in the infiltrate were CD25 
(green)/Foxp3 (red) double-positive. (F) As controls, many CD25 positive (green) cells 
were found within a class I mismatched kidney graft that was rejected in a cellular 
manner, but most of them were FoxP3 negative (red). 
(Figure taken from Okumi et al., 2013.  Permission given by Wiley Online Library to 
use Figure.) 
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Figure 5: Histological analysis of renal allografts. Biopsy specimens on day 22 from the 
73-day survivor in Group C showed severe rejection in the kidney from a naïve animal (A, 
H&E x100), but only minimal cell infiltrate in the kidney from an LTT animal (B, PAS 
x100). Day 28 biopsy specimens from the 28-day survivor in Group E showed severe 
diffuse interstitial hemorrhage and cellular infiltrate in the kidney from a naïve animal (C, 
H&E x100) and glomerular changes but much less interstitial hemorrhage in the kidney 
graft from an LTT animal (D, H&E x100). Representative histological findings on day 60 
from long-term acceptors in Group E showed minimal mononuclear cell infiltrate without 
chronic vasculopathy in the kidney grafts from both the naïve animal (E, H&E x200) and 
the LTT animal (F, H&E x200). Biopsies of the naive graft in long-term acceptors in Group 
E 21 days after the removal of the tolerated graft showed minimal cell infiltrates with no 
evidence of glomerulitis or vasculitis (G, H&E x200). 
(Figure taken from Okumi et al., 2013.  Permission given by Wiley Online Library to use 
figure.) 
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 Figure 6: Experimental protocol for Group E. The adoptive transfer donors (LTT 
animals) received 10 mL DST/kg body weight 1 week before leukapheresis. The adoptive 
transfer recipients were treated with 150 rads WBI and given 2.5 × 10
9
 PBMCs/kg (recipient 
body weight) from the adoptive transfer donor 1 day before kidney transplantation. The 
recipient then received both a class I mismatched kidney from a naïve SLA
gg
 pig and a long-
term tolerated kidney allograft (SLA
gg
) from the adoptive transfer donor without further 
immunosuppresssion. In order to assess graft function of SLA
gg
 kidneys grafts from naïve 
animals, two of three animals underwent graftectomy of the tolerant grafts from LTT donors 
on days 76 and 107, respectively. 
(Figure taken from Okumi et al., 2013. Permission given by Wiley Online Library to use 
Figure.) 
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Figure 7: Representative results of CML and co-culture CML assays for the 
long-term acceptor animals in Group E. (A) CML assays 30 and 60 days after 
primary transplant, as well as 75 days after removal of the LTT kidney showed 
donor-specific unresponsiveness. Recipient responses to donor stimulation are 
shown with solid lines and boxes, while responses to third party stimulation are 
shown with dotted lines and striped boxes. (B) Coculture assay performed at 126 
days showed that recipient PBMCs inhibited naïve CTL responses against donor 
antigens nearly 100% (red line with an arrow) when primed with donor antigen. 
(Figure taken from Okumi et al., 2013.  Permission given by Wiley Online Library 
to use Figure.) 
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DISCUSSION 
Tregs are vital in maintaining immunological balance.  The two main kinds of 
Tregs are the natural Tregs (nTreg) that are thymus derived and the inducible Tregs 
(iTreg) that are derived from naïve T cells in the periphery in a tolerogenic environment.  
The iTregs must be stimulated by donor antigen to expand.  Both iTregs and nTregs are 
CD4
+
CD25
+
Foxp3
+ 
and play a role in tolerance.  Foxp3 is the transcription factor that 
determines what happens to Tregs and must be expressed for Tregs to exert their 
regulatory effects.  The environment and  the types of signals that a T cell receives will 
determine its lineage (Burrell, Nakayama, Xu, Brinkman, & Bromberg, 2012).  
  Importantly, Tregs have been found to play important roles in the induction and 
maintenance of tolerance.  The presence of Tregs has been documented in kidney, 
cardiac, and skin grafts, as well as in the periphery.  Tregs have been shown to suppress 
helper T cell and effector T cell function as well as modulate APCs so they can not 
present graft antigen and endothelial cell status that can trigger inflammation (Burrell et 
al., 2012).  Tregs have been shown to be regulatory by generating cytokines like IL-10.  
Nevertheless, a great deal of work remains to be done to fully understand the role of 
Tregs in tolerance.  
We based our study on the fact that Tregs have been shown to suppress rejection 
of anti-donor cytotoxic T cells in vitro (Ierino et al., 1999; Ierino et al., 1998).  Our study 
has displayed the importance of Tregs that are present in the peripheral blood and part of 
the infiltrate of kidney grafts.  We were able to induce systemic tolerance of naïve class I 
mismatched kidneys by adoptive transfer of donor primed PBMCs and long-term tolerant 
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kidneys using only 150 rads of WBI on recipient swine.  This is the first time adoptive 
transfer of tolerance has been induced and maintained in large animals to our 
understanding. 
In our study, through CML and co-culture assays, we showed the beneficial 
effects of donor-specific transfusion in LTT animals by increasing the suppressive effects 
of the Tregs.  We used DST to increase Tregs in our adoptive transfer donors.  One of 
three animals in group C which received a kidney from a LTT donor that was DST 
primed survived for 73 days, compared to the longest survival in Group D of 46 days 
without DST priming.  The rest of the animals rejected, thus showing a minimal effect of 
DST alone.  Future studies need to study the effects of DST in vivo.  The effect of DST 
could potentially be the result of Treg expansion.  The in vivo expansion of Tregs would 
represent an enormous breakthrough, as these cells could be used as part of a cell therapy 
treatment for the induction of tolerance. 
Kidney grafts that were transplanted from tolerant animals seem to play a role in 
inducing infectious tolerance, where Tregs create a regulatory environment where they 
promote expansion of new Tregs that are donor-antigen specific (Burrell et al., 2012).  In 
the 73 day Group C survivor and 46 day Group D survivor there was less cell infiltrate or 
vasculitis in the transplanted graft as compared to the naïve graft.  The apparent 
protection of the tolerant kidney may be due to passenger graft infiltrating cells, 
immunoregulatory renal tubular cells (RTEC’s), and less immunogeneic donor APCs.  
Also, the passenger T regulatory cells that have been found in LTT graft may regulate a 
systemic tolerant response after adoptive transfer (Cobbold et al., 2004; Graca, Cobbold, 
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& Waldmann, 2002).  In addition, the chemokine/cytokine milieu of LTT kidneys allows 
for the expansion of Tregs.  Consistent with this, Foxp3 has been seen to be up-regulated 
in tolerated allografts (Lee et al., 2005).  In addition, IL-10 has been documented in the 
milieu and may also play a role in creating a protective environment (Blancho et al., 
1995).   
Naïve grafts have a large number of donor MHC-type dendritic cells, while LTT 
animals have few or no donor-type dendritic cells.  Understanding the role these APCs 
play could help distinguish if the protective aspect in LTT kidneys was due to the 
absence of the direct pathway of antigen presentation.  At the same time, tolerogenic 
dendritic cells have been shown to be capable of inducing donor-specific T-regs.  In 
addition, a positive feedback loop has been seen where these donor-specific T-regs are 
able to go back and induce the tolerogenic dendritic cells.  This may play a role in 
maintaining tolerance as the graft consistently provides antigen to the periphery in order 
to amplify and keep T-reg suppressive function (Burrell et al., 2012).  Future studies are 
needed to examine the role of these dendritic cells in transplantation and determine how 
they in turn interact with T-regs.   
While donor-specific transfusions and PBMC infusion from LTT animals did not 
have a great effect on inducing tolerance, transfer of DST primed PBMC and kidneys 
from LTT animals successfully induced tolerance of naïve class I mismatched kidneys.  
Thus, we believe that the cells from the periphery and in the kidney infiltrate played an 
important role in maintaining tolerance.  As with most processes in the human body, the 
peripheral and central components work together.  Maintaining tolerance needs 
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interactions between the kidney graft and the periphery.  We believe that the transferred 
Tregs travel to the LTT kidney where they undergo an increase in potency and/or 
expansion in number caused by antigens from the donor renal graft.  To translate our 
findings to the clinic, we must understand the characteristics of the infiltrate in tolerated 
kidney grafts and investigate the complex interactions that are occurring between the 
tolerated kidney and the periphery.  Understanding the mechanisms and timing of the 
graft infiltrating Tregs and peripheral Tregs may allow for tolerance induction without a 
long-term tolerant kidney.   
In tolerance it appears that nTregs can go directly to the graft as they are already 
present, while iTregs must first be produced in the periphery graft (Burrell et al., 2012).  
Thus, nTregs may play a greater role during the induction phase of tolerance, while 
iTregs are important in the maintenance phase of tolerance.  As more is understood about 
these subtypes, therapies to facilitate the expansion of one subtype may be the answer to 
inducing or maintaining tolerance.    
Some new studies in transplantation include the use of a new FDA approved 
immunosuppressive drug belatacept and study of potential biomarkers that can enhance 
transplantation tolerance (Burrell et al., 2012).  Some of the latest approaches that have 
used T-regs include transfection of activated CD4 cells with Foxp3 to give Treg status, 
using regulatory cytokines to induce Tregs, treating patients with immunosuppressive 
drugs that do not suppress Tregs, and treating patients with drugs that will stimulate 
nTregs (Burrell et al., 2012).  We believe that by understanding the roles of Tregs and 
being able to manipulate them further, therapies that use Tregs may enable us to utilize 
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the suppressive nature of Tregs to induce and maintain tolerance.  Manipulating Tregs in 
therapeutic manners to suppress rejection will require a fine balance to exploit the 
beneficial effects of Tregs suppressive effects to induce and maintain tolerance, while not 
affecting the rest of the normal immunological responses.  In conclusion, the proof that 
Tregs can be harnessed to induce and maintain tolerance through adoptive transfer will 
require further understanding of the mechanisms and functions of these cells. 
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